{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T12:11:45Z","timestamp":1781525505614,"version":"3.54.1"},"reference-count":29,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2024,2,25]],"date-time":"2024-02-25T00:00:00Z","timestamp":1708819200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Hematological Oncology"],"published-print":{"date-parts":[[2024,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Gain\/amplification of 1q21 (\u22653 copies), a chromosomal abnormality frequently observed in multiple myeloma, can negatively affect prognosis, due to its involvement in resistance to anti\u2010myeloma therapy and disease progression. In this updated subgroup analysis of the randomized, Phase 3 IKEMA study (NCT03275285) in relapsed\/refractory multiple myeloma (RRMM), we evaluated progression\u2010free survival (PFS) and depth of response with the anti\u2010CD38 antibody isatuximab plus carfilzomib\u2010dexamethasone (Isa\u2010Kd) versus Kd, in 1q21+ patients and related subgroups, at long\u2010term follow\u2010up (44.2\u00a0months). Our analysis included patients with 1q21+ (\u22653 copies, with\/without high\u2010risk chromosomal abnormality [HRCA]), isolated 1q21+ (\u22653 copies, without HRCA), gain(1q21) (3 copies, with\/without HRCA), and amp(1q21) (\u22654 copies, with\/without HRCA). PFS benefit was achieved with Isa\u2010Kd versus Kd in patients with 1q21+ (HR 0.58, 95% CI: 0.37\u20130.92), with isolated 1q21+ (HR 0.49, 95% CI: 0.27\u20130.92), with gain(1q21), or amp(1q21), consistent with the overall population and prior interim 1q21+ subgroup analyses. Median PFS with Isa\u2010Kd versus Kd was 25.8 versus 16.2\u00a0months in 1q21+ patients and 38.2 versus 16.2\u00a0months in patients with isolated 1q21+. Clinically meaningful, higher rates of very good partial response or better, complete response or better (\u2265CR), minimal residual disease (MRD) negativity, and MRD negativity and \u2265CR were reached with Isa\u2010Kd versus Kd in patients with 1q21+, isolated 1q21+, gain(1q21), or amp(1q21). In Isa\u2010Kd and Kd, the MRD negativity and \u2265CR rate was 29.3% versus 15.4% in 1q21+ patients, 36.2% versus 12.9% in patients with isolated 1q21+, 27.9% versus 13.5% in patients with gain(1q21), and 31.3% versus 20.0% in patients with amp(1q21), respectively. In conclusion, addition of Isa to Kd in triplet combination therapy has shown PFS benefit and deeper responses, compared with Kd, in 1q21+ patients at higher risk of progression, including patients with isolated 1q21+, gain(1q21), and amp(1q21), thus supporting Isa\u2010Kd an effective treatment option for patients with RRMM.<\/jats:p>","DOI":"10.1002\/hon.3258","type":"journal-article","created":{"date-parts":[[2024,2,25]],"date-time":"2024-02-25T05:39:58Z","timestamp":1708839598000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Isatuximab in combination with carfilzomib and dexamethasone in 1q21+ patients with relapsed\/refractory multiple myeloma: Long\u2010term outcomes in the Phase 3 IKEMA study"],"prefix":"10.1002","volume":"42","author":[{"given":"Thierry","family":"Facon","sequence":"first","affiliation":[{"name":"Department of Hematology Lille University Hospital  Lille France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Moreau","sequence":"additional","affiliation":[{"name":"Department of Hematology University Hospital H\u00f4tel\u2010Dieu  Nantes France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"\u0160picka","sequence":"additional","affiliation":[{"name":"Department of Hematology 1st Faculty of Medicine Charles University and General Hospital  Prague Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenshi","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Myeloma\/Amyloidosis Center Japanese Red Cross Medical Center  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwee","family":"Yong","sequence":"additional","affiliation":[{"name":"Department of Haematology University College Hospital  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Mikhael","sequence":"additional","affiliation":[{"name":"Translational Genomics Research Institute City of Hope Cancer Center  Phoenix Arizona USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taro","family":"Fukao","sequence":"additional","affiliation":[{"name":"Sanofi Global Oncology  Cambridge Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamlesh","family":"Bisht","sequence":"additional","affiliation":[{"name":"Sanofi Global Oncology  Cambridge Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole M.","family":"Armstrong","sequence":"additional","affiliation":[{"name":"Sanofi Global Medical Affairs  Cambridge Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandrine","family":"Mac\u00e9","sequence":"additional","affiliation":[{"name":"Sanofi Research and Development  Chilly\u2010Mazarin France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie\u2010Laure","family":"Risse","sequence":"additional","affiliation":[{"name":"Sanofi Research and Development  Vitry\u2010Sur\u2010Seine France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Martin","sequence":"additional","affiliation":[{"name":"University of California San Francisco Medical Center  San Francisco California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,2,25]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation\u20102017.1.508"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1080\/14737140.2021.1837627"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13205154"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102006\u201003\u2010009910"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408\u2010021\u201000474\u20108"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2021.1983427"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2018"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26590"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2021.278888"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23705"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12546"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408\u2010019\u20100254\u20100"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019001425"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277\u2010021\u201004704\u20108"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140\u20106736(19)32556\u20105"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140\u20106736(21)00592\u20104"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408\u2010023\u201000797\u20108"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2022.280660"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277\u2010022\u201004917\u20105"},{"key":"e_1_2_11_21_1","volume-title":"Prescribing Information","author":"Sarclisa","year":"2022"},{"key":"e_1_2_11_22_1","volume-title":"Sarclisa, INN\u2010Isatuximab","author":"European Medicines Agency","year":"2021"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023010026"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1470\u20102045(16)30206\u20106"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102020\u2010136613"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885\u2010020\u201007077\u20109"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.hs9.0000970628.27700.c7"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16292"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277\u2010022\u201004978\u20106"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102016\u201003\u2010703439"}],"container-title":["Hematological Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hon.3258","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T04:35:22Z","timestamp":1758688522000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hon.3258"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,25]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["10.1002\/hon.3258"],"URL":"https:\/\/doi.org\/10.1002\/hon.3258","archive":["Portico"],"relation":{},"ISSN":["0278-0232","1099-1069"],"issn-type":[{"value":"0278-0232","type":"print"},{"value":"1099-1069","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,25]]},"assertion":[{"value":"2023-09-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-02-03","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-02-25","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e3258"}}